A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

This study is testing whether combining pembrolizumab (an immunotherapy drug) with isolated limb infusion — a technique that delivers a high concentration of chemotherapy directly into an arm or leg — can improve outcomes for people with advanced sarcoma (a cancer of connective tissue) affecting a limb. **You may be eligible if...** - You are 12 years or older - You have a confirmed diagnosis of advanced or metastatic sarcoma in an arm or leg - You have already received at least one prior cancer treatment (chemotherapy, immunotherapy, or targeted therapy) or have decided not to pursue the standard option - You are eligible for both pembrolizumab and the isolated limb infusion procedure based on your doctor's assessment - You are in reasonably good physical condition (ECOG 0–2) - Your blood counts and organ function meet minimum requirements **You may NOT be eligible if...** - Your sarcoma is not located in a limb - You have not yet received any prior systemic cancer treatment (and are still eligible for standard options) - You have conditions that make the limb procedure or immunotherapy unsafe - You are pregnant Talk to your doctor to see if this trial is right for you.